Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Travoprost Intraocular, high elution · 1 trial · 1 indication
Change from baseline in IOP (measured in mmHg) at week 12. Negative values represent reductions in IOP from baseline.
| Arm | Type | Description |
|---|---|---|
| Travoprost Intraocular Implant, high elution | EXPERIMENTAL | This implant will be surgically implanted and elute travoprost, a prostaglandin. |
| Travoprost Intraocular Implant, low elution | EXPERIMENTAL | This implant will be surgically implanted and elute travoprost, a prostaglandin. |
| Timolol Maleate Ophthalmic Solution, 0.5% | ACTIVE_COMPARATOR | Timolol, a beta blocker, will be dosed twice daily |
| Name | Type | Description |
|---|---|---|
| Travoprost Intraocular Implant, high elution | DRUG | Surgical implant placed within the eye to elute travoprost. |
| Travoprost Intraocular Implant, low elution | DRUG | Surgical implant placed within the eye to elute travoprost |
| Timolol Maleate Ophthalmic Solution, 0.5% | DRUG | Instillation of one drop of timolol in the study eye twice daily |
Inclusion Criteria: * Open angle glaucoma Exclusion Criteria: * Uveitic, neovascular, or angle closure glaucoma; or glaucoma associated with vascular disorders. * Functionally significant visual field loss, including severe nerve fiber bundle defects. * Prior glaucoma surgery. * Uncontrolled syst...
Travoprost Intraocular, high elution is an investigational small molecule being developed for open-angle glaucoma. It is delivered as an intraocular implant and was studied in a Phase 2 clinical trial comparing it to timolol ophthalmic solution in patients with open-angle glaucoma.
Travoprost Intraocular, high elution is being developed by Glaukos Corporation, which trades under the ticker GKOS. The company is conducting clinical research on this intraocular implant for the treatment of open-angle glaucoma.
Travoprost Intraocular, high elution is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug remains under investigation for open-angle glaucoma.
Travoprost Intraocular, high elution was studied in a completed Phase 2 trial with the identifier NCT02754596. The trial, titled 'Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution,' enrolled 154 participants in the United States and was randomized, double-blind, and active-controlled.
Travoprost Intraocular, high elution is a specific formulation of travoprost, a prostaglandin analog, delivered as an intraocular implant. It is designed for sustained release within the eye and is being studied specifically for open-angle glaucoma, distinguishing it from other travoprost formulations.